Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Mallinckrodt
McKinsey
Johnson and Johnson
Merck

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Patent: 10,265,374

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,265,374
Title:Occidiofungin formations and uses thereof
Abstract: Disclosed are occidiofungin formulations and uses thereof for the treatment of proliferative disorders, such as cancer. Methods of producing the disclosed occidiofungin formulations are also provided. Further, methods of treating a subject with the formulations are provided. In some embodiments, the formulations include occidiofungin and one or more cyclodextrins. The formulations may optionally further comprise an additional chemotherapeutic agent for treating the proliferative disease, lipid vesicles, and/or aqueous solvents (including pharmaceutically acceptable buffers and/or exceipients).
Inventor(s): Smith; James L. (College Station, TX), Pruett; Stephen (Starkville, MS), Austin; Frank (Starkville, MS), Lu; Shien (Starkville, MS), Akshaya; Ravichandran (Bryan, TX), Laihing; Steven (College Station, TX)
Assignee: MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX)
Application Number:15/510,801
Patent Claims:see list of patent claims

Details for Patent 10,265,374

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX) 2034-09-12 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX) 2034-09-12 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX) 2034-09-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX) 2034-09-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX) 2034-09-12 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX) 2034-09-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
McKinsey
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.